Medical technology company AngioDynamics Inc (NASDAQ: ANGO) reported on Wednesday that the two-year results from the PRESERVE pivotal trial of its NanoKnife System demonstrated sustained oncologic control and a consistent safety profile in patients with intermediate-risk prostate cancer.

The prospective, single-arm IDE study evaluated focal irreversible electroporation (IRE) in 121 patients with Gleason Grade Group 2-3 prostate cancer across 17 US clinical centres, in collaboration with the Society of Urologic Oncology Clinical Trials Consortium. Twelve-month results previously showed an 80% freedom-from-treatment-failure rate among protocol-biopsied patients, published in European Urology in July 2025.

At 24 months, 94.4% of analysis-eligible patients completed follow-up, with no new treatment failures reported among those assessed. One clinically indicated biopsy was negative for cancer, and 97% of patients recorded PSA levels below baseline. No new device- or procedure-related adverse events were observed between 12 and 24 months.

The findings reinforce longer-term international evidence supporting focal IRE as a treatment option designed to preserve quality of life while maintaining durable cancer control in intermediate-risk prostate cancer patients.